This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2023 Aug;18(8):e84-e85.

doi: 10.1016/j.jtho.2023.05.018.

Letter to the Editor: Reply to Kus and Aktas

Joao V Alessi¹, Mark M Awad²

Affiliations

Affiliations

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Boston, Massachusetts.
² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Boston, Massachusetts. Electronic address: mark_awad@dfci.harvard.edu.

PMID: 37479334
DOI: 10.1016/j.jtho.2023.05.018

Free article

Comment

Letter to the Editor: Reply to Kus and Aktas

Joao V Alessi et al. J Thorac Oncol. 2023 Aug.

Free article

. 2023 Aug;18(8):e84-e85.

doi: 10.1016/j.jtho.2023.05.018.

Authors

Joao V Alessi¹, Mark M Awad²

Affiliations

¹ Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Boston, Massachusetts.
² Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Boston, Massachusetts. Electronic address: mark_awad@dfci.harvard.edu.

PMID: 37479334
DOI: 10.1016/j.jtho.2023.05.018

No abstract available

PubMed Disclaimer

Comment on

In the Presence of KRAS Comutations With STK11 or KEAP1 Monoimmunotherapy Does Not Work, but Is Not Chemoimmunotherapy Also an Overtreatment?
Kus T, Aktas G. Kus T, et al. J Thorac Oncol. 2023 Aug;18(8):e83-e84. doi: 10.1016/j.jtho.2023.03.026. J Thorac Oncol. 2023. PMID: 37479333 No abstract available.

Publication types

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.